Retatrutide and Ozempic are being compared directly, in the population Ozempic is actually approved for. NCT06260722 puts retatrutide against semaglutide in 1,250 adults with type 2 diabetes, and it is enrolled and running. That makes this the one retatrutide comparison where the trial in progress matches the question people are asking. Until it reports, what exists is one drug approved for diabetes and one approved for nothing.
Side by side
| Retatrutide | Ozempic | |
|---|---|---|
| Status | Investigational, phase 3 | FDA approved |
| Approved for | — | Type 2 diabetes |
| Weight loss use | Under investigation | Off-label |
| Targets | GLP-1, GIP, glucagon | GLP-1 |
| HbA1c reduction | −1.94% at 40 wks (12 mg) | ~−1.5 to −1.8% (2 mg) |
| Weight loss, type 2 diabetes | 15.3% at 40 wks | No weight endpoint in label |
| Maximum dose | 12 mg weekly (trials) | 2 mg weekly |
| Cardiovascular indication | No — trial running | Yes, in type 2 diabetes |
| Can you get it | No | Yes, by prescription |
The one comparison that is properly matched
Most cross-trial comparisons in this field mix populations. This one does not have to. Retatrutide's first phase 3 trial, TRANSCEND-T2D-1, enrolled 537 adults with type 2 diabetes inadequately controlled by diet and exercise — which is close to the population Ozempic is licensed for.
| In type 2 diabetes | HbA1c | Weight | Duration |
|---|---|---|---|
| Retatrutide 12 mg | −1.94% | −15.3% | 40 weeks |
| Semaglutide 1–2 mg | ~−1.5 to −1.8% | ~−6% (secondary) | 40–68 weeks |
Retatrutide lowered HbA1c further and produced substantially more weight loss, in a shorter trial. Both are phase 3, both in the same patient type — a much closer comparison than most in this field, though still separate studies rather than a head-to-head.
The head-to-head is NCT06260722, 1,250 adults with type 2 diabetes, retatrutide against semaglutide, phase 3, enrolled and running. It has not reported.
If your question is weight, Ozempic is the wrong comparison
Ozempic is licensed for type 2 diabetes. It has no weight-loss indication and its label publishes no weight endpoint, so any figure quoted for "Ozempic weight loss" is either a secondary observation from a diabetes trial or a number lifted from Wegovy — the same molecule at a higher dose, 2.4 mg against Ozempic's 2 mg ceiling.
If weight is what you are asking about, the properly matched comparison is retatrutide vs Wegovy, where both drugs have weight as a measured endpoint. Ozempic at 2 mg produces less weight loss than the figures usually attributed to it.
Where the third receptor might matter most
The glucagon arm is the argument for retatrutide and also the reason to watch it carefully in diabetes.
Glucagon raises blood sugar in isolation, which is the opposite of what a diabetes drug should do. The premise is that pairing it with two incretin receptors offsets the glucose effect while keeping the increase in energy expenditure. TRANSCEND-T2D-1 is the first real test of that premise at scale, and it held: HbA1c fell by 1.94% at the top dose, with no severe hypoglycaemia reported. Adding a glucose-raising hormone to a diabetes treatment and getting the best glycaemic result in the trial is a genuinely non-obvious outcome.
What remains unresolved is what it does over years, and whether the dose-dependent heart rate increases seen in phase 2 matter in a population already at cardiovascular risk. The 10,000-patient outcomes trial is running and has not reported.
What Ozempic has today
- An approval. A licensed indication, a known dose, a pharmacy that dispenses it.
- A cardiovascular indication in adults with type 2 diabetes and established cardiovascular disease — proven in an outcomes trial rather than inferred.
- Insurance coverage. Diabetes drugs are paid for where weight drugs are refused, which for many people is the whole decision.
- Years of post-marketing data across millions of patients, which is the only way rare effects ever surface.
Retatrutide has none of these, and what is sold under its name online is not a substitute: three such products analysed in Australia contained 51%, 165% and 190% of their labelled dose. See can you buy retatrutide.
Which, and when
- Type 2 diabetes, treatment today: Ozempic or another approved option. Retatrutide is not available.
- Which is the better diabetes drug: retatrutide, on one phase 3 trial each, pending the direct comparison.
- Weight loss: the wrong comparison — use retatrutide vs Wegovy.
- Established cardiovascular disease: Ozempic, which has proven the benefit rather than being tested for it.
- Tracking the change: the GLP-1 pipeline tracker.
Scientific References
3 sources- 1
Bajaj HS, Welch M, Shah P, et al.
Efficacy and safety of retatrutide in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial
The Lancet · 407(10546) · 2026PMID: 42250575
- 2
Jastreboff AM, Kaplan LM, Frías JP, et al.
Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
New England Journal of Medicine · 389(6) · 2023PMID: 37366315
NEJM - 3
U.S. National Library of Medicine
NCT06260722 — Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes, phase 3, 1,250 participants; status read 13 August 2026
ClinicalTrials.gov · 2026
References open in a new tab. Content is reviewed against peer-reviewed literature as part of our editorial policy.
About the author
Editor, Modern Weight Science
Claudiu Gheorghe is the editor of Modern Weight Science. He is not a physician. His role is to synthesize peer-reviewed studies, clinical-trial data, and FDA prescribing information into clear, plain-language explanations, and to make sure every factual claim on the site traces back to a cited source. Any decision about starting, changing, or stopping a medication belongs with a licensed clinician who knows your history.
Every claim is checked against peer-reviewed research through our review process and fact-checking policy.
Frequently Asked Questions
Is retatrutide better than Ozempic?
In separate phase 3 trials in the same population, retatrutide lowered HbA1c by 1.94% and body weight by 15.3% at 40 weeks, ahead of semaglutide's roughly 1.5 to 1.8% and 6% over longer trials. A direct comparison in 1,250 adults with type 2 diabetes is enrolled and running. But Ozempic is approved, prescribable and covered by insurance, and retatrutide is none of those.
Is there a trial comparing retatrutide and Ozempic?
Yes — NCT06260722, a phase 3 study of retatrutide against semaglutide in 1,250 adults with type 2 diabetes. It is enrolled and running and has not reported. That population matches Ozempic's licensed indication, which makes it the most directly relevant trial to this question.
How much weight loss on retatrutide versus Ozempic?
Retatrutide reached 15.3% at 40 weeks in adults with type 2 diabetes. Ozempic has no weight endpoint in its label at all — it is approved for diabetes, and weight reduction appears only as a secondary observation. Any Ozempic weight figure you see is usually Wegovy's, the same molecule at 2.4 mg rather than Ozempic's 2 mg ceiling. For a weight comparison, use retatrutide vs Wegovy.
Does retatrutide cause low blood sugar?
No severe hypoglycaemia was reported in its phase 3 diabetes trial of 537 people over 40 weeks. That is notable because retatrutide activates the glucagon receptor, and glucagon raises blood sugar in isolation. Pairing it with two incretin receptors appears to offset that, and the trial produced the strongest HbA1c reduction in the study at the top dose.
Should I switch from Ozempic to retatrutide?
You cannot. Retatrutide is not approved anywhere, so no clinician can prescribe it and no pharmacy can dispense it, apart from a narrow compassionate use programme. Ozempic has an approved indication, a known dose, a proven cardiovascular benefit in diabetes with established heart disease, and years of post-marketing data.
Continue learning
Where to read next
Not medical advice. This guide is for general education only. GLP-1 medications, dosing, and treatment suitability are decisions for you and a licensed clinician who knows your full medical history.